Home 
Bratislava Medical Journal Ahead of print BLL_2023_074
Bratislava Medical Journal Ahead of print BLL_2023_074
Journal info
|
||||
Select Journal
Journals
Acta Virologica Bratislava Medical Journal Ahead of print 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 Endocrine Regulations General Physiology and Biophysics Neoplasma Studia Psychologica Cardiology Letters Psychológia a patopsych. dieťaťa Kovove Materialy-Metallic Materials Slovenská hudbaWebshop Cart
Your Cart is currently empty.
Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.
BLL_2023_074 |
||
| Title: Predictive value of infliximab trough levels in maintenance therapy for 5-year sustained clinical remission in patients with inflammatory bowel disease | ||
| Author: Yashar JALALI, Anna GOJDICOVA, Igor STURDIK, Jozef TOTH, Tomas KOLLER, Martin HUORKA, Monika JALALI, Juraj PAYER, Tibor HLAVATY | ||
| Abstract: BACKGROUND: Despite long-term use of infliximab (IFX) in IBD treatment, its optimized use is unclear due to its complicated pharmacokinetics/dynamics. Hence, the predictive value of IFX trough levels (TL) is important in treatment management. METHODS: We performed a prospective, cross-sectional, observational study with 74 IBD patients treated with IFX (mean 9.1 years, SD ± 3). TL was measured during maintenance therapy, in which maintenance of remission was followed for 5 years. RESULTS: TL > 3 µg/ml during maintenance therapy was a significant predictor of clinical remission in 5 years in UC patients (82 % vs 62 %, p 3 µg/ml during maintenance therapy in a cohort of IBD patients (p = 0.05). Deviations in percentage of remission and fraction of relapses in TL categories were insignificant in a cohort of CD patients (85 % vs 74 %, p > 0.05). CONCLUSIONS: TL > 3 µg/ml during maintenance therapy is a strong predictor of sustained clinical remission for 5 years in UC patients. The use of combination therapy with AZA, due to its significant association with high TL, may have a practical benefit in achieving better clinical outcomes in UC patients (Tab. 2, Fig. 10, Ref. 20). |
||
| Keywords: trough levels, inflammatory bowel disease, ulcerative colitis, Crohn’s disease, infliximab, therapeutic drug monitoring. | ||
| Published online: 12-May-2023 | ||
| Year: , Volume: , Issue: | Page From: , Page To: | |
| doi:10.4149/BLL_2023_074 |
||
|
|
 download file |
|